zinc finger and BTB domain containing 16Genealiases: PLZF · ZNF145
Q-omics provides the consensus-scored ZBTB16 profile across patient tissues and cancer cell-line models. ZBTB16 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZBTB16 is differentially expressed in 16, with the highest sampling consensus in THCA. Additionally, ZBTB16 RNA expression shows 19,926 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, THCA, and LSCC as cancer lineages where ZBTB16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB16 survival associations across molecular data types. ZBTB16 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB16 RNA expression–survival associations across cancer types. High ZBTB16 expression shows unfavorable associations in OV and LUSC, but favorable associations in KIRC, MESO, LIHC and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZBTB16 RNA expression.
This table summarizes ZBTB16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZBTB16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB16 shows lower tumor expression in THCA, BLCA, LUAD, COAD, HNSC and LUSC. The THCA box plot shows higher ZBTB16 RNA expression in normal versus tumor tissue (log2 FC = −2.755, t-test p < 0.001).
This table shows molecular features associated with ZBTB16 in patient tissues and cancer cell lines. In patient samples, ZBTB16 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBTB16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BONE.
